The Wistar Institute Appoints Legal and Life Sciences Expert Squire Servance to Its Board of Trustees

PHILADELPHIA — (MARCH, 30, 2023) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Squire Servance, founder and managing partner for the Princeton, NJ-based life sciences-focused investment firm Syridex Bio, to its Board of Trustees, where he will serve on the Audit, Business Development and Scientific Advisory Committees.

An influential and driven business executive, Servance brings extensive knowledge of the life sciences industry through his leadership of Syridex Bio, an impact-driven, life sciences-focused investment firm geared towards investing in therapies that accelerate global health equity.

“Wistar is doing innovative, impactful biomedical research with a track record of hitting above its weight at an exciting time for the life sciences sector,” said Squire Servance. “My career has been steeped in the life sciences as a patent attorney, on the business development side and as an investor so I’m excited to bolster their work in these areas. The scientists are doing ambitious science, but the educational component and STEM equity is equally critical, and Wistar is leading the way training the next leaders in the life sciences space.”

Prior to founding Syridex Bio, Servance was general counsel, corporate secretary and chief compliance officer for Repligen Corporation, headquartered in Waltham, Mass., overseeing all legal functions and leading the development and implementation of an enterprise risk management program. He was associate general counsel for Baxter International, Inc., of Deerfield, Ill.; legal counsel for India-based Dr. Reddy’s Laboratories; was a barred patent attorney with Morgan, Lewis & Bockius, LLP, in Philadelphia; and clerked for Judge Jerome A. Holmes of the U.S. Court of Appeals for the Tenth Circuit.

“Squire’s unmatched strategic, legal perspective, ranging from intellectual property and business development and licensing to risk management, paired with his extensive technical knowledge of the life sciences industry, will be instrumental in helping Wistar achieve higher levels of prominence in the worldwide biomedical research community as we work to achieve global impact through bold, innovative research ideas,” said Dario C. Altieri, M.D., Wistar president and CEO, Director of the Ellen and Ronald Caplan Cancer Center, and Robert and Penny Fox Distinguished Professor. “His leadership will be invaluable as we accelerate research advances from bench to bedside through high-caliber science and collaboration among scientific investigators and academic-industry partners to create scientific breakthroughs that change the future of human health.”

Servance earned his J.D. from Duke University School of Law and his MBA from Duke’s Fuqua School of Business. He completed his undergraduate studies in biomedical engineering and cell biology and neuroscience at Rutgers, the State University of New Jersey School of Engineering.

In addition to his service with Wistar, Servance serves as board advisor and member of the Finance and Audit committee for Thompson Island Outward Bound Education Center, Inc.; and is a board director for Metropolitan Camden Habitat for Humanity, Inc. A highly active volunteer, voice and leader for both Duke and Rutgers over the last decade, he serves on the board of the Duke Alumni Association and is board trustee Audit Committee member for Rutgers and is a member of Alpha Phi Alpha Fraternity, Inc.

###

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside. wistar.org